Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI, FVT

Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA


IRVINE, Calif., Feb. 16, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting. Results from the European and Canadian Phase III study, EVB-003, will be presented by one of the study investigators Berthold Rzany, M.D., during the AAD Meeting in San Diego on Saturday, February 17 at 10:12 AM in room 6D.  

 (PRNewsfoto/Evolus Inc.)

About PrabotulinumtoxinA

PrabotulinumtoxinA is a 900 kDa purified botulinum toxin type A complex.  The product candidate's Biologics License Application (BLA) is currently under review by the U.S. Food and Drug Administration (FDA).  The product candidate's Marketing Authorization Application (MAA) is currently also under review by the European Medicines Agency (EMA). The FDA application is for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.  The EMA application is for temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity has an important psychological impact in adult patients.

About Evolus, Inc.

Evolus, Inc. is a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. Evolus, Inc. focuses on the self-pay aesthetic market and our lead product candidate is an injectable 900 kDa purified botulinum toxin type A complex.

Evolus Press Contacts:

September Riharb, Vice President, Marketing 
Tel: +1-805-764-6300
Email: [email protected]

Jeff Plumer, Vice President, Legal
Tel: +1-949-284-4555
Email: [email protected]

SOURCE Evolus, Inc.


These press releases may also interest you

at 04:00
Halfpricesoft.com offers a seamless and secure solution for in-house payroll processing with the l atest 2024 ezPaycheck YTD feature for those switching to the program, mid-year. The application is also combine d with features that have long...

at 04:00
U Power Limited (the "Company" or "U Power"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that the Company held an extraordinary general meeting of...

at 04:00
"The tourism data for Milan in 2023 reached an all-time high, and it's a success we must share among many stakeholders, both public and private, including the dense network of accommodation facilities in the city. We need virtuous examples like Hotel...

at 03:59
Timekettle, a fast-growing cross-language communication solutions innovator, has successfully wrapped up its #SpringTravelWithTimekettle campaign on Instagram. Running from March 18 to 24, Timekettle encouraged global travelers to share their...

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 03:44
Bitrue, a leading cryptocurrency exchange serving over 10 million users globally, announces a focus on user behavior analysis to further develop the utility of its native token, Bitrue Coin (BTR). "Understanding how our users interact with BTR is...



News published on and distributed by: